Cure8 research brief
A reproducible animal model of perianal fistulizing Crohn’s disease could help researchers study how fistulas form and persist and provide a test platform for new therapies before human trials.
Researchers studying perianal Crohn’s disease, preclinical drug developers, and clinicians interested in the pathophysiology of pfCD.
This preclinical research article describes a two-stage rat model that aims to mimic human perianal fistulizing Crohn’s disease (pfCD). Researchers induced chronic colitis with repeated rectal TNBS, created a fistulous tract mechanically, and instilled TNBS locally to maintain fistula-associated inflammation.
They evaluated the model with colonoscopy, perineal ultrasound, MRI, histology, immunofluorescence, western blotting for barrier proteins (MUC2, ZO-1, Occludin), and measured inflammatory markers (IL-23, IL-12, TNF-α, NGAL) in serum and colon tissue.
The authors report that the model produced persistent colitis, imaging-confirmed fistulous tracts, reduced expression of barrier proteins, increased inflammatory markers, and immune-cell marker patterns (CD86, MPO) in fistula tissue that resembled specimens from treatment‑naïve pfCD patients.
The paper positions the model as a reproducible platform for studying mechanisms and testing therapies in a preclinical setting. This report is an abstract/posted preprint on Research Square and presents an animal model rather than a clinical trial or treatment.
It does not provide clinical treatment data or human patient outcomes, and any therapeutic implications would require further validation and testing.
This is a preclinical animal-study report (rat model) presented as a posted article/abstract; it does not report human clinical trial results. Findings in animal models may not translate directly to patients and require additional validation before informing clinical care.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study tests whether adding MRI-based transmural assessment to a fecal-calprotectin–guided (CALM) strategy improves the ability to keep people with Crohn’s disease in corticosteroid-free clinical remission and may...
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
This trial tests a novel cell-derived extracellular vesicle therapy (DB-3Q) for people with Crohn’s disease who have not responded to standard advanced therapies. It may offer a different biologic approach if proven safe...
